HBM Holdings Past Earnings Performance
Past criteria checks 1/6
HBM Holdings has been growing earnings at an average annual rate of 36.6%, while the Biotechs industry saw earnings growing at 38% annually. Revenues have been growing at an average rate of 43.4% per year. HBM Holdings's return on equity is 2.2%, and it has net margins of 7.3%.
Key information
36.64%
Earnings growth rate
59.06%
EPS growth rate
| Biotechs Industry Growth | 11.00% |
| Revenue growth rate | 43.44% |
| Return on equity | 2.21% |
| Net Margin | 7.29% |
| Last Earnings Update | 31 Dec 2024 |
Recent past performance updates
Recent updates
What HBM Holdings Limited's (HKG:2142) 51% Share Price Gain Is Not Telling You
May 07
HBM Holdings' (HKG:2142) Shareholders Have More To Worry About Than Only Soft Earnings
Apr 29HBM Holdings Limited (HKG:2142) Stock Catapults 78% Though Its Price And Business Still Lag The Industry
Feb 20HBM Holdings Limited (HKG:2142) Stock Catapults 58% Though Its Price And Business Still Lag The Industry
Jan 01Investors Still Aren't Entirely Convinced By HBM Holdings Limited's (HKG:2142) Revenues Despite 30% Price Jump
Oct 02Not Many Are Piling Into HBM Holdings Limited (HKG:2142) Just Yet
Jul 18HBM Holdings (HKG:2142) Seems To Use Debt Quite Sensibly
May 23Take Care Before Jumping Onto HBM Holdings Limited (HKG:2142) Even Though It's 28% Cheaper
Apr 12HBM Holdings Limited (HKG:2142) Surges 25% Yet Its Low P/S Is No Reason For Excitement
Jan 01We're Not Very Worried About HBM Holdings' (HKG:2142) Cash Burn Rate
Feb 08Revenue & Expenses Breakdown
How HBM Holdings makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Dec 24 | 38 | 3 | 16 | 21 |
| 30 Sep 24 | 55 | 12 | 19 | 25 |
| 30 Jun 24 | 72 | 21 | 22 | 30 |
| 31 Mar 24 | 81 | 22 | 21 | 37 |
| 31 Dec 23 | 90 | 23 | 21 | 45 |
| 30 Sep 23 | 72 | -19 | 21 | 62 |
| 30 Jun 23 | 54 | -61 | 21 | 80 |
| 31 Mar 23 | 47 | -99 | 24 | 108 |
| 31 Dec 22 | 41 | -137 | 27 | 135 |
| 30 Sep 22 | 35 | -143 | 35 | 142 |
| 30 Jun 22 | 30 | -149 | 43 | 150 |
| 31 Mar 22 | 17 | -144 | 42 | 128 |
| 31 Dec 21 | 4 | -138 | 40 | 107 |
| 30 Sep 21 | 7 | -224 | 46 | 94 |
| 30 Jun 21 | 10 | -310 | 53 | 81 |
| 31 Mar 21 | 12 | -303 | 50 | 68 |
| 31 Dec 20 | 14 | -296 | 46 | 55 |
| 30 Sep 20 | 13 | -187 | 28 | 46 |
| 30 Jun 20 | 11 | -78 | 11 | 37 |
| 31 Mar 20 | 8 | -73 | 11 | 43 |
| 31 Dec 19 | 5 | -67 | 11 | 49 |
| 31 Dec 18 | 1 | -35 | 6 | 32 |
Quality Earnings: 2142 has a large one-off gain of $2.0M impacting its last 12 months of financial results to 31st December, 2024.
Growing Profit Margin: 2142's current net profit margins (7.3%) are lower than last year (25.5%).
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: 2142 has become profitable over the past 5 years, growing earnings by 36.6% per year.
Accelerating Growth: 2142's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.
Earnings vs Industry: 2142 had negative earnings growth (-87.8%) over the past year, making it difficult to compare to the Biotechs industry average (14.2%).
Return on Equity
High ROE: 2142's Return on Equity (2.2%) is considered low.
Return on Assets
Return on Capital Employed
Discover strong past performing companies
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/05/13 02:00 |
| End of Day Share Price | 2025/05/13 00:00 |
| Earnings | 2024/12/31 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
HBM Holdings Limited is covered by 8 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Bo Li | BofA Global Research |
| Tony Ren | CLSA |
| null null | Credit Suisse |